Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
The prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of PD-L1 on clinicopathlogical findings and survival outcomes in sarcoma. A comprehensive search in PubMed, Embase and the Cochrane Library was cond...
Saved in:
Published in | Oncotarget Vol. 8; no. 35; pp. 59570 - 59580 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Impact Journals LLC
29.08.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of PD-L1 on clinicopathlogical findings and survival outcomes in sarcoma.
A comprehensive search in PubMed, Embase and the Cochrane Library was conducted for relevant studies. The odds ratios or hazard ratios, at 95% confidence intervals were used as measures for investigation of the correlation between PD-L1 expression and clinicopathlogical features or survival outcomes.
Fourteen eligible studies comprising 868 patients were selected for analysis. Pooled hazard ratios indicated that the association of PD-L1 expression with overall survival in bone sarcoma (osteosarcoma and chondrosarcoma) patients was statistically significant (1.987, 95% CI: 1.224-3.224,
= 0.005), as was its association with event-free survival in bone and soft-tissue sarcoma patients (3.868, 95% CI: 2.298-6.511,
= 0.000). Additionally, the expression of PD-L1 was positively correlated with the infiltration of programmed death 1 (PD-1) positive T-lymphocytes (OR: 4.012, 95% CI: 2.391-6.733,
= 0.000).
Our meta-analysis indicated that high PD-L1 expression is likely to be a negative factor for patients with sarcomas and that it predicts worse survival outcomes. |
---|---|
AbstractList | The prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of PD-L1 on clinicopathlogical findings and survival outcomes in sarcoma.
A comprehensive search in PubMed, Embase and the Cochrane Library was conducted for relevant studies. The odds ratios or hazard ratios, at 95% confidence intervals were used as measures for investigation of the correlation between PD-L1 expression and clinicopathlogical features or survival outcomes.
Fourteen eligible studies comprising 868 patients were selected for analysis. Pooled hazard ratios indicated that the association of PD-L1 expression with overall survival in bone sarcoma (osteosarcoma and chondrosarcoma) patients was statistically significant (1.987, 95% CI: 1.224-3.224,
= 0.005), as was its association with event-free survival in bone and soft-tissue sarcoma patients (3.868, 95% CI: 2.298-6.511,
= 0.000). Additionally, the expression of PD-L1 was positively correlated with the infiltration of programmed death 1 (PD-1) positive T-lymphocytes (OR: 4.012, 95% CI: 2.391-6.733,
= 0.000).
Our meta-analysis indicated that high PD-L1 expression is likely to be a negative factor for patients with sarcomas and that it predicts worse survival outcomes. BACKGROUNDThe prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of PD-L1 on clinicopathlogical findings and survival outcomes in sarcoma.MATERIALS AND METHODSA comprehensive search in PubMed, Embase and the Cochrane Library was conducted for relevant studies. The odds ratios or hazard ratios, at 95% confidence intervals were used as measures for investigation of the correlation between PD-L1 expression and clinicopathlogical features or survival outcomes.RESULTSFourteen eligible studies comprising 868 patients were selected for analysis. Pooled hazard ratios indicated that the association of PD-L1 expression with overall survival in bone sarcoma (osteosarcoma and chondrosarcoma) patients was statistically significant (1.987, 95% CI: 1.224-3.224, p = 0.005), as was its association with event-free survival in bone and soft-tissue sarcoma patients (3.868, 95% CI: 2.298-6.511, p = 0.000). Additionally, the expression of PD-L1 was positively correlated with the infiltration of programmed death 1 (PD-1) positive T-lymphocytes (OR: 4.012, 95% CI: 2.391-6.733, p = 0.000).CONCLUSIONSOur meta-analysis indicated that high PD-L1 expression is likely to be a negative factor for patients with sarcomas and that it predicts worse survival outcomes. |
Author | Yao, Jihang Tang, Yajun Jin, Zheng Zhu, Zhenhua Yang, Guang Yuan, Xiaowei Zhang, Mei Sun, Dahui |
AuthorAffiliation | 3 College of Chemistry, Jilin University, Changchun, China 2 Department of Immunology, College of Basic Medical sciences, Jilin University, Changchun, China 1 Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China |
AuthorAffiliation_xml | – name: 2 Department of Immunology, College of Basic Medical sciences, Jilin University, Changchun, China – name: 3 College of Chemistry, Jilin University, Changchun, China – name: 1 Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China |
Author_xml | – sequence: 1 givenname: Zhenhua surname: Zhu fullname: Zhu, Zhenhua organization: Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China – sequence: 2 givenname: Zheng surname: Jin fullname: Jin, Zheng organization: Department of Immunology, College of Basic Medical sciences, Jilin University, Changchun, China – sequence: 3 givenname: Mei surname: Zhang fullname: Zhang, Mei organization: College of Chemistry, Jilin University, Changchun, China – sequence: 4 givenname: Yajun surname: Tang fullname: Tang, Yajun organization: College of Chemistry, Jilin University, Changchun, China – sequence: 5 givenname: Guang surname: Yang fullname: Yang, Guang organization: Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China – sequence: 6 givenname: Xiaowei surname: Yuan fullname: Yuan, Xiaowei organization: Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China – sequence: 7 givenname: Jihang surname: Yao fullname: Yao, Jihang organization: Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China – sequence: 8 givenname: Dahui surname: Sun fullname: Sun, Dahui organization: Department of Orthopaedic Trauma, The First Hospital of Jilin University, Changchun, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28938660$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUclOwzAQtRCIpfABXJCPXAJeEsfmgIQqNgkJDnC2Js6kDUrsYqeV-vdEtGxzmdHMe29G847Irg8eCTnl7IJrJcVl8C4MEGc4XHDDld4hh9zkJhNFIXf_1AfkJKV3NkaRl1qYfXIgtJFaKXZIHl9imPmQhtbRFXRLpKGhi7EXoe-xpjXCMM-6dga-ppy2niaILvRwRYH2OEAGHrp1atMx2WugS3iyzRPydnf7On3Inp7vH6c3T5nLhRgykTMUTNeqMQWTWjKD4EAhzxVoWcmqdABOSm4a19QSVFlXqKu8bjA3kGs5Idcb3cWyGi906IcInV3Etoe4tgFa-3_i27mdhZUtFONloUaB861ADB9LTIPt2-Sw68BjWCY7Pk6UjAtmRijfQF0MKUVsftZwZr9csL8u2C8XRs7Z3_t-GN8_l5-49ok8 |
CitedBy_id | crossref_primary_10_3389_fonc_2020_00749 crossref_primary_10_3390_ijms20010170 crossref_primary_10_1097_MD_0000000000014006 crossref_primary_10_3389_fimmu_2021_775761 crossref_primary_10_3390_cells9040976 crossref_primary_10_1186_s13293_020_00347_y crossref_primary_10_3892_ol_2018_9264 crossref_primary_10_1016_j_jbo_2019_100221 crossref_primary_10_3390_ijms21155207 crossref_primary_10_1038_s41598_020_65895_0 crossref_primary_10_1186_s12931_018_0885_x crossref_primary_10_3389_fendo_2023_1187289 crossref_primary_10_3390_cells10051240 crossref_primary_10_1002_adhm_202400623 crossref_primary_10_1007_s00262_020_02552_5 crossref_primary_10_1016_j_semcancer_2019_05_018 crossref_primary_10_3390_cells13110977 crossref_primary_10_1177_1724600818774464 crossref_primary_10_4143_crt_2017_529 crossref_primary_10_1080_14737140_2018_1413939 crossref_primary_10_1007_s00428_022_03358_9 crossref_primary_10_3390_ijms24032858 crossref_primary_10_1007_s10456_020_09716_y crossref_primary_10_3390_cancers12113392 crossref_primary_10_18821_0869_2084_2020_65_11_669_675 crossref_primary_10_3390_cancers13030363 crossref_primary_10_3390_cancers13061317 crossref_primary_10_4143_crt_2021_496 |
Cites_doi | 10.1186/s12885-016-2451-6 10.1182/blood-2016-08-731885 10.1038/leu.2016.214 10.1097/CJI.0000000000000065 10.1038/nrurol.2015.287 10.1080/2162402X.2016.1278100 10.1371/journal.pone.0082870 10.1097/BLO.0b013e318059b8c9 10.3892/or.2015.3933 10.1158/2326-6066.CIR-13-0224 10.3322/caac.20073 10.21037/jtd.2017.03.104 10.1080/2162402X.2015.1029701 10.1016/j.ctrv.2017.01.007 10.2217/imt-2016-0025 10.1016/j.oooo.2016.12.002 10.1038/modpathol.2016.108 10.1016/j.suc.2016.05.012 10.1080/2162402X.2016.1253657 10.1007/s12032-016-0807-z 10.1186/s12929-017-0329-9 10.18632/oncotarget.17022 10.1007/s00262-016-1925-3 10.1016/j.critrevonc.2016.03.007 10.1016/j.humpath.2014.11.001 10.1038/srep30093 10.5306/wjco.v8.i2.145 10.1007/s00262-017-1954-6 10.1186/1745-6215-8-16 10.1093/annonc/mdw388.05z 10.1136/gutjnl-2015-310839 |
ContentType | Journal Article |
Copyright | Copyright: © 2017 Zhu et al. 2017 |
Copyright_xml | – notice: Copyright: © 2017 Zhu et al. 2017 |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.18632/oncotarget.19168 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1949-2553 |
EndPage | 59580 |
ExternalDocumentID | 10_18632_oncotarget_19168 28938660 |
Genre | Journal Article |
GroupedDBID | --- 53G ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK FRJ GX1 HYE KQ8 M48 M~E NPM OK1 PGMZT RPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c422t-240e208d6f95038309eaca6e146a83b3b7caac3319fcfd3a67dbe8b4dfe49a483 |
IEDL.DBID | RPM |
ISSN | 1949-2553 |
IngestDate | Tue Sep 17 21:22:03 EDT 2024 Fri Aug 16 03:45:01 EDT 2024 Fri Aug 23 00:24:28 EDT 2024 Tue Aug 27 13:47:17 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 35 |
Keywords | meta-analysis programmed death-ligand 1 sarcoma prognosis survival |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c422t-240e208d6f95038309eaca6e146a83b3b7caac3319fcfd3a67dbe8b4dfe49a483 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601756/ |
PMID | 28938660 |
PQID | 1942701209 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5601756 proquest_miscellaneous_1942701209 crossref_primary_10_18632_oncotarget_19168 pubmed_primary_28938660 |
PublicationCentury | 2000 |
PublicationDate | 2017-08-29 |
PublicationDateYYYYMMDD | 2017-08-29 |
PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-29 day: 29 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncotarget |
PublicationTitleAlternate | Oncotarget |
PublicationYear | 2017 |
Publisher | Impact Journals LLC |
Publisher_xml | – name: Impact Journals LLC |
References | Blattman (18) 2015; 38 Jang (15) 2013; 8 Honjo (8) 2017; 24 Abdel-Rahman (24) 2016; 101 Liu (26) 2015; 8 Batista (11) 2017; 123 Takahashi (13) 2016; 6 Yang (29) 2015; 8 Hornicek (21) 2014; 2 Kwok (25) 2015; 33 Tap (12) 2015; 46 Ferrari (19) 2016; 27 Kourie (1) 2017; 8 Stewart (3) 2007; 459 10 Gonlusen (20) 2016; 33 Vogelzang (7) 2017; 54 Ma (27) 2017; 11 Sydes (32) 2007; 8 Bovee (17) 2016; 29 Gorlick (16) 2016; 6 Kelly (30) 2017; 66 Ahn (14) 2016; 16 Li (9) 2017; 9 Gosain (33) 2016; 96 Mougiakakos (4) 2017; 31 Cleton-Jansen (22) 2017; 66 Mamessier (31) 2017; 6 Weber (6) 2017; 66 Ward (2) 2010; 60 Thoma (28) 2016; 13 Abdel-Rahman (23) 2016; 8 Avigan (5) 2017; 129 |
References_xml | – volume: 16 start-page: 434 year: 2016 ident: 14 article-title: Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma publication-title: BMC Cancer doi: 10.1186/s12885-016-2451-6 contributor: fullname: Ahn – volume: 129 start-page: 275 year: 2017 ident: 5 article-title: Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? publication-title: Blood doi: 10.1182/blood-2016-08-731885 contributor: fullname: Avigan – volume: 31 start-page: 470 year: 2017 ident: 4 article-title: The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia publication-title: Leukemia doi: 10.1038/leu.2016.214 contributor: fullname: Mougiakakos – volume: 38 start-page: 96 year: 2015 ident: 18 article-title: Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions publication-title: J Immunother doi: 10.1097/CJI.0000000000000065 contributor: fullname: Blattman – volume: 13 start-page: 5 year: 2016 ident: 28 article-title: Prostate cancer: PD-L1 expression is common and indicates poor prognosis publication-title: Nat Rev Urol doi: 10.1038/nrurol.2015.287 contributor: fullname: Thoma – volume: 6 start-page: e1278100 year: 2017 ident: 31 article-title: PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas publication-title: OncoImmunology doi: 10.1080/2162402X.2016.1278100 contributor: fullname: Mamessier – volume: 8 start-page: e82870 year: 2013 ident: 15 article-title: Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas publication-title: PLoS One doi: 10.1371/journal.pone.0082870 contributor: fullname: Jang – volume: 459 start-page: 40 year: 2007 ident: 3 article-title: Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report publication-title: Clin Orthop Relat Res doi: 10.1097/BLO.0b013e318059b8c9 contributor: fullname: Stewart – volume: 8 start-page: 14595 year: 2015 ident: 26 article-title: Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis publication-title: Int J Clin Exp Med contributor: fullname: Liu – volume: 33 start-page: 3075 year: 2015 ident: 25 article-title: The prognostic significance of PD-L1 in bladder cancer publication-title: Oncol Rep doi: 10.3892/or.2015.3933 contributor: fullname: Kwok – volume: 2 start-page: 690 year: 2014 ident: 21 article-title: Programmed cell death ligand 1 expression in osteosarcoma publication-title: Cancer immunology research doi: 10.1158/2326-6066.CIR-13-0224 contributor: fullname: Hornicek – volume: 60 start-page: 277 year: 2010 ident: 2 article-title: Cancer statistics, 2010 publication-title: CA Cancer J Clin doi: 10.3322/caac.20073 contributor: fullname: Ward – volume: 9 start-page: 655 year: 2017 ident: 9 article-title: Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials publication-title: J Thorac Dis doi: 10.21037/jtd.2017.03.104 contributor: fullname: Li – ident: 10 doi: 10.1080/2162402X.2015.1029701 – volume: 54 start-page: 58 year: 2017 ident: 7 article-title: A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2017.01.007 contributor: fullname: Vogelzang – volume: 8 start-page: 1081 year: 2016 ident: 23 article-title: PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis publication-title: Immunotherapy doi: 10.2217/imt-2016-0025 contributor: fullname: Abdel-Rahman – volume: 123 start-page: e188 year: 2017 ident: 11 article-title: Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol doi: 10.1016/j.oooo.2016.12.002 contributor: fullname: Batista – volume: 29 start-page: 1028 year: 2016 ident: 17 article-title: Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype publication-title: Mod Pathol doi: 10.1038/modpathol.2016.108 contributor: fullname: Bovee – volume: 96 start-page: 1107 year: 2016 ident: 33 article-title: Pediatric Sarcomas publication-title: Surg Clin North Am doi: 10.1016/j.suc.2016.05.012 contributor: fullname: Gosain – volume: 6 start-page: e1253657 year: 2016 ident: 13 article-title: Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1253657 contributor: fullname: Takahashi – volume: 33 year: 2016 ident: 20 article-title: Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas publication-title: Med Oncol doi: 10.1007/s12032-016-0807-z contributor: fullname: Gonlusen – volume: 24 start-page: 26 year: 2017 ident: 8 article-title: Cancer immunotherapies targeting the PD-1 signaling pathway publication-title: J Biomed Sci doi: 10.1186/s12929-017-0329-9 contributor: fullname: Honjo – volume: 11 year: 2017 ident: 27 article-title: PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.17022 contributor: fullname: Ma – volume: 66 start-page: 119 year: 2017 ident: 22 article-title: Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-016-1925-3 contributor: fullname: Cleton-Jansen – volume: 101 start-page: 75 year: 2016 ident: 24 article-title: Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2016.03.007 contributor: fullname: Abdel-Rahman – volume: 46 start-page: 357 year: 2015 ident: 12 article-title: Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment publication-title: Hum Pathol doi: 10.1016/j.humpath.2014.11.001 contributor: fullname: Tap – volume: 6 start-page: 30093 year: 2016 ident: 16 article-title: Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma publication-title: Sci Rep doi: 10.1038/srep30093 contributor: fullname: Gorlick – volume: 8 start-page: 11084 year: 2015 ident: 29 article-title: Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors publication-title: Int J Clin Exp Pathol contributor: fullname: Yang – volume: 8 start-page: 145 year: 2017 ident: 1 article-title: Immunotherapies in sarcoma: Updates and future perspectives publication-title: World J Clin Oncol doi: 10.5306/wjco.v8.i2.145 contributor: fullname: Kourie – volume: 66 start-page: 551 year: 2017 ident: 6 article-title: PD-1 and PD-L1 antibodies in cancer: current status and future directions publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-017-1954-6 contributor: fullname: Weber – volume: 8 start-page: 16 year: 2007 ident: 32 article-title: Practical methods for incorporating summary time-to-event data into meta-analysis publication-title: Trials doi: 10.1186/1745-6215-8-16 contributor: fullname: Sydes – volume: 27 start-page: 1399PD year: 2016 ident: 19 article-title: PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma publication-title: Ann Oncol doi: 10.1093/annonc/mdw388.05z contributor: fullname: Ferrari – volume: 66 start-page: 794 year: 2017 ident: 30 article-title: Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma publication-title: Gut doi: 10.1136/gutjnl-2015-310839 contributor: fullname: Kelly |
SSID | ssj0000547829 |
Score | 2.399012 |
Snippet | The prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of... BACKGROUNDThe prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 59570 |
SubjectTerms | Meta-Analysis |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA61XryI4qu-iOBJ2LrdpElWEBGxVKHiwUJvS7Kb1UK7q-0W9N87s4_aak_els3j8GWSb4aZfCHk3Pe1DzzBHW1dDFDgy3AjHeBSLQxrWzdPtPeeRLfPHwftQY1Uz1uVAE5Xhnb4nlR_Mmp-fnzdwIa_xg2vBPMuU9QxyAunmxB-CLVG1j3OOBp8r_T2C6lvDnzol7nNlSNRGxgYXBWSlQtE9cf7_F1EucBKnS2yWbqT9LZY_21Ss8kOeXiepFg_B_8oinlbmsa0LMSCqWiEbp8zGr7qJKItOkzoFMw9HesrqunYZtrRpVTJLul37l_uuk75ZIITcs_LMFdiPVdFIvZR54W5PhysWlg4D7VihhkZah0y2HdxGEdMCxkZqwyPYst9zRXbI_UkTewBoS0juWCSRxB0cBuCI6kM8Jy1EGFIwd0GuajwCd4LZYwAIwrENfjBNchxbZCzCsEA7BeTEjqx6WwKzdyT-Q3eBtkvEJ1PVy1Fg8glrOcdUBt7uSUZvuUa2RhoyrY4_PfII7LhIYO7eEnlmNSzycyegP-RmdPcqr4BPy3eFQ priority: 102 providerName: Scholars Portal |
Title | Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28938660 https://search.proquest.com/docview/1942701209 https://pubmed.ncbi.nlm.nih.gov/PMC5601756 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4NAEJ60PXkxGl_10ayJJxNayi674M00ajWp6cEmvZFdWJSkQNPS_-8sj9rqzQshLGzIMOw3X2bmW4A735c-4gSzpLYNQcEzxZSwEEslV9TVdplon7zz8Yy9zd15C9ymF6Ys2g9V0s8WaT9LvsraymUaDpo6scF0MjIsQrh80Ia2oHSHoleC3gxRz68zmB6nziA3OgdlYXUf6Qk3e_Qhz6BeJUy5A0d_YszfpZI72PN8BId10Egeq5c7hpbOTuB1uspNlRxeI0ayW5M8JnW5FU5FIhPcWYvkU2YRGZIkI2t06jyVD0SSVBfSkrUgySnMnp8-RmOr3hjBCpnjFCYjoh3bi3jsGzUXavu4fEqucdWTHlVUiVDKkOLfFYdxRCUXkdKeYlGsmS-ZR8-gk-WZvgAyVIJxKliE1ILpEMNFTyGaaY08QnBmd-G-sU-wrPQvAsMbjF2DH7sGpV27cNtYMEAvNakHmel8s8Zh5oiyT7cL55VFt9M1n6ILYs_W2xuMAvb-CDpGqYRdO8Llv5-8ggPH4LRtWlGuoVOsNvoGo4xC9aD9Mh_iccK8Xulh34MD1nk |
link.rule.ids | 230,315,733,786,790,891,2236,24346,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LToQwFL3RcaEbH_E1PmviygSGoaUFd8ZoxscYF2rckRaKEmdgMsNs_HpveeioK90RCqRwuL33pKenAMdBIAPME8yS2jEEBY8UU8LCXCq5op52yon2_h3vPbLrZ-95DrxmLUwp2o9UameDoZ2lr6W2cjSMOo1OrHPfPzcsQni8Mw8LGK-uN0PSK0tvhnkvqOcwfU7dTm6cDkpptY0EhZtd-pBpUL-yppxJSL-qzJ9iyZnsc7kCT02_K9HJmz0tlB29_7B0_POLrcJyXY-Ss6p5DeZ0tg5X9-PcCPDwHDFu4JrkCamVXNhHEpu60RqkLzKLSZekGZlgvORDeUokGepCWrL2OtmAx8uLh_OeVe-5YEXMdQsz2aJdx495EhijGOoEODJLrnFAlT5VVIlIyohi4CZRElPJRay0r1icaBZI5tNNaGV5preBdJVgnAoWI2thOsJK1FeYKLVGiiI4c9pw0nz4cFRZa4SGkhjAwi_AwhKwNhw10IQYAGZWQ2Y6n06wmbmiXALchq0Kqs_HNRi3QXwD8fMCY679vQWhKU22ayh2_n3nISz2Hvq34e3V3c0uLLmmHHDMipc9aBXjqd7HYqZQB-Wv-wGp4vai |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB1BkRAXFrGV1UickLI0du2EGwIqyqYeQEJcIjtxoIImFU0vfD3jLKUtN25R7ERJXsYzT35-BjgNAhlgnmCW1K4hKHikmBIW5lLJFW1rt5hof3jkN8_s9qX9MrXVVyHaj1TfTj8Hdtp_L7SVw0Hk1Doxp_dwaViEaHNnGCfOIixhzHpiiqiXtt4Mc19QzWP6nHpOZtwOCnm1jSSFm536kG1Qv7SnnEpKfyrNecHkVAbqrMFr_eyl8OTDHufKjr7nbB3_9XLrsFrVpeSi7LIBCzrdhG7vKzNCPDxHjCu4JllCKkUXPieJTf1offbfZBqTFumnZIRxkw3kOZFkoHNpycrzZAueO9dPlzdWtfeCFTHPy82ki_ZcP-ZJYAxjqBvgCC25xoFV-lRRJSIpI4oBnERJTCUXsdK-YnGiWSCZT7ehkWap3gXSUoJxKliM7IXpCCtSX2HC1BqpiuDMbcJZ_fHDYWmxERpqYkALf0ELC9CacFLDE2IgmNkNmepsPMJm5oliKXATdkq4JrercW6CmAFy0sGYbM-2IDyF2XYFx96_rzyG5d5VJ7zvPt7tw4pnqgLXLHw5gEb-NdaHWNPk6qj4e38AX5T5Ig |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+programmed+death-ligand+1+in+sarcoma%3A+a+meta-analysis&rft.jtitle=Oncotarget&rft.au=Zhu%2C+Zhenhua&rft.au=Jin%2C+Zheng&rft.au=Zhang%2C+Mei&rft.au=Tang%2C+Yajun&rft.date=2017-08-29&rft.pub=Impact+Journals+LLC&rft.eissn=1949-2553&rft.volume=8&rft.issue=35&rft.spage=59570&rft.epage=59580&rft_id=info:doi/10.18632%2Foncotarget.19168&rft_id=info%3Apmid%2F28938660&rft.externalDBID=PMC5601756 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |